Tag: Industry
-
Industry Report #10｜First ANGPTL3 Small Nucleic Acid Drug Submits Clinical Trial Application in China
Angiopoietin-like protein 3 (ANGPTL3) is a protein involved in fat metabolism and blood vessel formation. Variations in the ANGPTL3 gene can lead to familial hypercholesterolemia (HoFH). On January 31, the clinical trial application for JS401 injection, jointly developed by Runjia Pharmaceuticals and Shanghai Junshi Bioscience and Technology Co., Ltd., received approval from the National Medical…
-
Weekly Industry 8｜Two news stories on gene editing therapies
FDA Calls Off Verve to Target High Cholesterol Treatment; Gene-Edited T-Cells for Tumors Trial Yields Results
-
Weekly Industry 4 | Amgen Obesity Therapy Phase I Progress, Weight Loss Drugs Remain in Short Supply
Patients treated with both high/low doses showed more significant weight loss with less severe side effects, potentially easing the supply of newer weight-loss drugs.
-
Industry Report #3｜Innovations in Antidepressants Reshaping the Chinese Market
According to the latest updates from the National Medical Products Administration, the first domestically developed and innovatively antidepressant drug with independent intellectual property rights, Ruoxinlin®, was approved for market launch on November 3rd. National Medical Products Administration Announcement [6] According to the latest updates from the National Medical Products Administration, Ruoxinlin®, an antidepressant drug independently…
-
【线上讲座】 – BrainCo: Dr. Neo Mohsenvand Guest Speaker Event
InT@UCLA 在本周四下午2-3点邀请到 Dr. Mohsenvand 带来线上讲座。📣 Dr. Mohsenvand 是 BrainCo 一家脑机接口（BMI）创业公司的研发负责人。他在 MIT Media Lab 下获得博士学位，兴趣领域包括：AI、ML、EEG和脑机接口、转化医学和VR/AR/MR等。
In Transcription. @UCLA 